The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of duration of bevacizumab (Bev) treatment in the prognosis of adults with recurrent malignant gliomas.
Mohamed Ali Hamza
No relevant relationships to disclose
Charles A. Conrad
Consultant or Advisory Role - Reata Pharmaceuticals
Stock Ownership - Reata Pharmaceuticals
Research Funding - Archer Biosciences
John Frederick De Groot
Consultant or Advisory Role - Genentech
Research Funding - Adnexus; AstraZeneca; Sanofi
Mark R. Gilbert
Consultant or Advisory Role - Abbott Laboratories; Genentech; Merck
Honoraria - Genentech; Merck
Research Funding - Genentech; Merck
Morris D. Groves
Consultant or Advisory Role - Genentech; Merck; Sanofi
Honoraria - Genentech; Merck; Sanofi
W. K. Alfred Yung
Consultant or Advisory Role - Actelion; Merck
Honoraria - Actelion; Merck; Novartis
Research Funding - Daiichi Sankyo; Novartis
Vinay K. Puduvalli
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Bayer; Celgene; Genentech; Merck